Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01336205 · ClinicalTrials.gov registry record · Phase 3

Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation

A Phase 3 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
844
Enrollment target

NCT01336205 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 844 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01336205, a Phase 3 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
844 participants
Enrollment target

Study Summary

The purpose of this study is to evaluate the long-term safety and tolerability of NKTR-118 treatment of opioid-induced constipation (OIC) in patients with non-cancer-related pain.

Interventions

  • DRUG Usual care
  • DRUG NKTR-118

Trial Details

FieldValue
Enrollment Target 844 participants
Start Date 2011-04
Est. Completion 2012-12
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT01336205

The ClinicalTrials.gov registry entry for NCT01336205 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 844 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Usual care is the first listed.

NCT01336205 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01336205 about?

NCT01336205 is a clinical study titled "Assessment of Long-term Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation". The purpose of this study is to evaluate the long-term safety and tolerability of NKTR-118 treatment of opioid-induced constipation (OIC) in patients with non-cancer-related pain.

What is the current status of trial NCT01336205?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 844 participants. The study started on 2011-04. Estimated completion is 2012-12.

What interventions are being tested in trial NCT01336205?

The interventions under investigation include: Usual care (DRUG), NKTR-118 (DRUG).

Who is sponsoring clinical trial NCT01336205?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.